CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Shares	Treasury Stock	Capital in Excess of Par Value	Accumulated Other Comprehensive Income/(Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023		191,384
Beginning balance at Dec. 31, 2023	$ 130,987	$ 19		$ 3,608,137	$ 80	$ (3,477,249)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under equity compensation plans (in shares)		525
Shares issued under equity compensation plans	3			3
Stock-based compensation	6,000			6,000
Repurchase of common stock from Bristol-Myers Squibb (in shares)		(8,285)	8,285
Repurchase of common stock from Bristol-Myers Squibb	(3,000)		$ (3,000)
Issuance of prefunded warrant	30,000			30,000
Comprehensive income (loss)	(37,285)				(483)	(36,802)
Ending balance (in shares) at Mar. 31, 2024		183,624
Ending balance at Mar. 31, 2024	$ 126,705	$ 19	$ (3,000)	3,644,140	(403)	(3,514,051)
Ending balance (in shares) at Mar. 31, 2024			8,285
Beginning balance (in shares) at Dec. 31, 2024	185,777	185,777
Beginning balance at Dec. 31, 2024	$ 60,737	$ 19	$ (3,000)	3,659,867	61	(3,596,210)
Beginning balance (in shares) at Dec. 31, 2024	8,285		8,285
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under equity compensation plans (in shares)		326
Shares issued under equity compensation plans	$ 7			7
Stock-based compensation	3,898			3,898
Comprehensive income (loss)	$ (50,904)				(22)	(50,882)
Ending balance (in shares) at Mar. 31, 2025	186,103	186,103
Ending balance at Mar. 31, 2025	$ 13,738	$ 19	$ (3,000)	$ 3,663,772	$ 39	$ (3,647,092)
Ending balance (in shares) at Mar. 31, 2025	8,285		8,285